管状支架腔内修复升主动脉病变的单中心经验
单中心回顾性分析2010至2017年24例不适合开放手术的高危升主动脉病变患者,采用Zenith Ascend TAA支架行腔内修复,30天生存率79%,结论认为该技术可行且早中期结果可接受,但再干预率较高。
要点
- 高危升主动脉病变患者行腔内修复可行,30天生存率79%。
- 再干预率12.5%,与操作复杂性相关。
- 围术期并发症包括卒中、心肌梗死和主动脉瓣反流。
核心结论
- 对于不适合开放手术的高危升主动脉病变患者,使用支架行腔内修复是可行的治疗选择,早中期结果可接受。
- Ascend TEVAR的复杂性可能导致较高的再干预率。
研究设计与样本
- 单中心回顾性研究,2010至2017年纳入24例升主动脉病变患者,平均年龄70±15岁(范围29-90),其中男性18例。
- 病变包括急慢性A型主动脉夹层16例、假性动脉瘤6例、脱位经皮主动脉瓣固定2例及其他适应症3例。
- 患者经心脏科及心脏和血管外科跨学科评估后入选,植入Zenith Ascend TAA Endovascular Graft,13例同时行其他手术。
- 共27例次Ascend TEVAR(24例初次,3例再干预),其中17例急诊、10例择期。
- 主要结局为30天生存率,次要结局为心血管并发症、中期生存率和再干预率。
主要发现
- 除1例外均获临床成功,30天生存率为79%(19/24)。
- 5例死亡中仅1例与植入支架直接相关。
- 术后30天内发生1例心肌梗死、2例主要卒中、1例真菌性假性动脉瘤、1例Ascend TEVAR所致重度主动脉瓣反流、1例轻微卒中,1例同期植入4分支腹主动脉支架后发生截瘫。
- 2例在30天内再干预,分别针对假性动脉瘤和主动脉瓣反流。
- 平均随访11个月(0-35个月)期间,1例晚期死亡(癌症),1例在10个月时因晚期Ia型内漏再干预(再干预率12.5%)。
临床怎么用
- 对于不适合开放手术的高危升主动脉病变患者,可考虑腔内修复作为替代方案。
- 需由心脏科、心脏外科和血管外科进行跨学科评估以筛选合适患者。
- 术后应密切监测卒中、心肌梗死、主动脉瓣反流和内漏等并发症,并警惕再干预可能。
局限性
- 单中心小样本回顾性研究,证据等级有限。
- 随访时间较短(平均11个月),中期结果需进一步验证。
- 患者选择存在异质性,且部分手术为急诊或同期联合手术,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To investigate the endovascular treatment of ascending aortic pathologies of high-risk patients unsuitable for open repair. Materials and Methods: From 2010 to 2017, 24 patients (mean age 70±15 years, range 29-90; 18 men) were treated at a single center for various pathologies of the ascending aorta, including acute or chronic type A aortic dissections (n=16), pseudoaneurysms (n=6), fixation of a dislocated percutaneous aortic valve (n=2), and miscellaneous indications (n=3). The patients were selected following an interdisciplinary case evaluation, attended by cardiologists and cardiac and vascular surgeons. The Zenith Ascend TAA Endovascular Graft was implanted; simultaneous procedures were performed in 13 patients. Of the total 27 Ascend TEVAR procedures (24 primary and 3 reinterventions), 17 were performed urgently and 10 electively. The primary outcome measure was 30-day survival. The secondary outcomes were cardiovascular complications, midterm survival, and reintervention rate. Results: Clinical success was achieved in all but 1 case. The 30-day survival was 79% (19/24); of the 5 deaths only 1 was directly related to the endograft implanted. In the 30-day postoperative period, there was 1 myocardial infarction, 2 major strokes, a mycotic pseudoaneurysm, a case of Ascend TEVAR-induced high-grade aortic insufficiency, and a minor stroke; 1 patient developed paraplegia after concurrent implantation of a 4-branched abdominal stent-graft. Two patients had a reintervention within 30 days for the pseudoaneurysm and the aortic insufficiency, respectively. During a mean follow-up of 11 months (0-35 months), there was 1 late death (cancer) and 1 additional reintervention at 10 months for a late type Ia endoleak (12.5% reintervention rate). Conclusion: Endovascular repair of ascending aortic pathologies with stent-grafts is a feasible treatment option with acceptable early and midterm outcomes in high-risk patients unsuitable for open surgery. The complexity of Ascend TEVAR might justify higher reintervention rates.
引用
- Tsilimparis N, Drewitz S, Detter C, et al. Endovascular Repair of Ascending Aortic Pathologies With Tubular Endografts: A Single-Center Experience. J Endovasc Ther. 2019. PMID: 31140362. doi:10.1177/1526602819852083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。